ASTRAZENECA PLC |
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 12.712,00 GBX | +0,49% |
|
-4,23% | +19,92% |
| 19:55 | AstraZeneca zegt dat proef met longkankermedicijn geen significante verbetering in algehele overleving laat zien | RE |
| 12:33 | ASTRAZENECA : UBS is niet overtuigd | ZD |
Groep AstraZeneca PLC: relatiegrafiek
Beursgenoteerde bedrijven van dezelfde groep: AstraZeneca PLC
| Onderneming | Marktkapitalisatie | Bedrijfsleider |
|---|---|---|
| ASTRAZENECA PHARMA INDIA LIMITED | 2,05 mld. | Siva Padmanabhan |
Privébedrijven die tot dezelfde groep behoren als ASTRAZENECA PLC
| Onderneming | Bedrijfsleider |
|---|---|
Astrazeneca Treasury Ltd.
 Astrazeneca Treasury Ltd. Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Treasury Ltd. functions as an investment holding British company. The company is based in Cambridge, UK. | - |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | - |
| Astrazeneca Holdings BV | - |
AstraZeneca India Pvt Ltd.
 AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology AstraZeneca India Pvt Ltd. operates as a biopharmaceutical company. The company was founded in 1979 and is headquartered in Bangalore, India. | Sivakumar Padmanabhan |
| AstraZeneca Finance LLC | - |
| Alexion Pharmaceuticals, Inc. /New/ | Marc Dunoyer |
AstraZeneca UK Ltd.
 AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Pascal Soriot |
